(Q40633560)

22 September 2017

title

Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency (English)

1 reference

22 September 2017

Scharrer I

1

1 reference

22 September 2017

publication date

1 July 1999

1 reference

22 September 2017

1 reference

22 September 2017

volume

5

1 reference

22 September 2017

issue

4

1 reference

22 September 2017

page(s)

253-259

1 reference

Treatment of factor VIII inhibitors: products and strategies

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00319.X

The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00319.X

Inhibitors in congenital haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00319.X

Newer concepts of blood coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00319.X

Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00319.X

The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00319.X

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1999.00319.X

10.1046/J.1365-2516.1999.00319.X

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference